Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
Summary
It is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with Cystic Fibrosis (CF) by its ability to reduce levels of toxic reactive oxygen and nitrogen compounds associated with the chronic inflammatory component of the disease. The primary objective of the study is to assess the safety of inhaled sodium pyruvate in 0.9% sodium chloride (saline) solution in people with CF. Further, to determine whether inhaled sodium pyruvate will improve lung function, as determined by spirometry, or reduced inflammatory markers in induced sputum of people with CF.
Description
Cystic fibrosis (CF) is the most common, lethal inherited disease of Caucasians. Approximately 30,000 people in the United States and 70,000 worldwide have a diagnosis of CF. It is caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) gene. The clinical manifestations characteristic of CF include progressive bronchiectatic lung disease with thick mucus production and colonization by Pseudomonas aeruginosa. The CFTR gene mutation results in altered cell transport properties, which affect both chloride and glutathione secretion. Chronic inflammation, associated with activated neutrophils and macrophages, is a common feature of CF. Highly reactive toxic oxygen (superoxide anion, free hydroxyl radical, hydrogen peroxide) and nitrogen species (nitric oxide, peroxynitrites) are abundant in the chronic inflammatory response in CF and appear to play a prominent role in the pathogenesis of this disease. These reactive oxygen and nitrogen species have been shown to be directly toxic to various mammalian tissues, including lung, via DNA damage and cell membrane lipid peroxidation. In addition, elevated levels of hydrogen peroxide and nitric oxide have been demonstrated in sputum and bronchoalveolar lavage fluid of patients with CF, asthma, and chronic obstructive pulmonary disease. Clearly reactive oxygen and nitrogen species are implicated in the pathogenesis of a variety of lung diseases including CF.
Sodium pyruvate is an antagonist of both reactive oxygen and nitrogen species. It also has the potential to increase intracellular levels of thiol compounds, major sources of intracellular anti-oxidants. Sodium pyruvate has been shown to act as an anti-inflammatory agent that can reduce the number of infiltrating neutrophils and levels of oxygen radicals at wound sites, thereby limiting the production of pro-inflammatory mediators. Thus, it is hypothesized that the inhalation of sodium pyruvate will reduce lung damage in patients with CF by its ability to reduce levels of toxic reactive oxygen and nitrogen species associated with the chronic inflammatory component of the disease.
The trial is a Phase I Safety Study that will be conducted in three Stages. The study is designed to assess the safety of administering sodium pyruvate inhalation therapy to CF subjects once a day for one day, then twice a day for one day, and finally, twice a day for four weeks. All testing, including the screening visit and Stage 1, and Stages 2 and 3, will be conducted at the University of Minnesota (UMN) General Clinical Research Center GCRC).
Stage 1 - Single dose inhalation - 24 hours (n=15) Participants with CF will receive a single dose of sodium pyruvate (5 ml in physiological saline) via a Pari-Jet hand-held nebulizer (Pari LC Plus® nebulizer system) , and will be followed at UMN GRC for four hours with a follow up telephone interview at 24 hours. Three concentrations (0.5 mM, 1.5 mM, and 5.0 mM) of sodium pyruvate solution will be studied. Five subjects will receive the lowest concentration of sodium pyruvate solution; then another five subjects will receive the middle dose of sodium pyruvate solution; and finally a third group of five subjects will receive the highest dose of sodium pyruvate solution.
Patients enrolled in Stage 1 will have one 6-hour visit at UMN GCRC. Following administration of a single 5-mL dose of either 0.5 mM, 1.5 mM, or 5.0 mM sodium pyruvate in 0.9% saline solution, the following tests will be performed:
Post Inhalation of Study Drug
Spirometry:
- Post inhalation 0.5 Hr
- Post inhalation 1 Hr
- Post inhalation 2 Hr
- Post inhalation 4 Hr
Sputum Induction:
- Post inhalation 1 Hr
SaO2:
- Post inhalation 0.5 Hr
- Post inhalation 1 Hr
- Post inhalation 2 Hr
- Post inhalation 4 Hr
End of Visit.
Blood and Urine Analysis
- Post inhalation 4 Hr
Electrocardiogram
- Post inhalation 4 Hr
Vital Signs
- Post inhalation 4 Hr
The parameters for safety monitoring will include spirometry, vital signs, ECG, SaO2, and routine blood and urine analysis, which will be conducted pre- and post- inhalation of sodium pyruvate. Follow up telephone interviews will also be conducted for each stage.
With regard to efficacy, spirometry, and induced sputum samples will be monitored pre- and post- inhalation of sodium pyruvate. Induced sputum samples will be evaluated for cellular content (total WBC and differential) and the fluid content assessed for total protein, total DNA, elastase, glutathione (GSH and GSSG), H2O2 and inflammatory cytokines (IL-1, IL-6, and IL-8, TNF-alpha).
Study Design
Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Conditions
Cystic Fibrosis
Intervention
Sodium Pyruvate in 0.9% Sodium Chloride Solution
Location
University of Minnesota Medical School, The Minnesota Cystic Fibrosis Center
Minneapolis
Minnesota
United States
55455
Status
Recruiting
Source
Emphycorp
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00308243
- Information obtained from ClinicalTrials.gov on July 15, 2010
Medical and Biotech [MESH] Definitions
Sodium, Dietary
Sodium or sodium compounds used in foods or as a food. The most frequently used compounds are sodium chloride or sodium glutamate.
Saline Solution, Hypertonic
Hypertonic sodium chloride solution. A solution having an osmotic pressure greater than that of physiologic salt solution (0.9 g NaCl in 100 ml purified water).
Sodium Chloride Symporter Inhibitors
Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.
Cystic Fibrosis Transmembrane Conductance Regulator
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
Sodium-potassium-chloride Symporters
A subclass of symporters that specifically transport SODIUM CHLORIDE and POTASSIUM CHLORIDE across cellular membranes in a tightly coupled process.
Clinical Trials
A Phase I Study of Inhaled Sodium Pyruvate for the Treatment of Cystic Fibrosis.
The primary objective of this study is to assess the safety of inhaled sodium pyruvate in people with Cystic Fibrosis (CF). Further, to determine whether inhaled sodium pyruvate will impro...
Safety and Efficacy Study of the Use of Sodium Pyruvate Bronchodilation in Asthmatics
Sodium pyruvate in sodium chloride solution will be delivered by nebulization to the lungs. It is believed that this administration will produce bronchodilation in asthmatics as determined...
Sodium Pyruvate Therapy in COPD Patients
In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects wit...
Durability of Hypertonic Saline for Enhancing Mucociliary Clearance in Cystic Fibrosis
Direct measurement of mucociliary and cough clearance (MCC/CC) has been used as a biomarker in cystic fibrosis (CF). Additional knowledge of the performance of this biomarker is needed to...
Prevention of Contrast Nephropathy by Sodium Bicarbonate Versus Sodium Chloride and N-acetylcysteine
The objective of this study is to assess the efficacy of sodium bicarbonate compared with sodium chloride and oral N-acetylcysteine (NAC ) pretreatment for prevention of contrast nephropat...
PubMed Articles
Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies.
Introduction: Several types of mutations in the cystic fibrosis transmembrane regulator (CFTR) gene lead to abnormal CFTR protein and alterations of chloride and sodium transmembrane transportation in...
Gene therapy for cystic fibrosis.
The report of the first patients with cystic fibrosis (CF) to receive cystic fibrosis transmembrane conductance regulator gene (CFTR) therapy appeared in 1993, and since then there have been more than...
BACKGROUND: The ACP 215 was a functional closed system for preparing glycerolized and deglycerolized RBCs, CSBT had approved the technique of long term storage glycerolized rare blood lower than -65 d...
Phenol formation in gamma radiolysis of aqueous benzene solution with sodium hypochlorite.
Phenol formation by gamma radiolysis of an aqueous benzene solution containing sodium hypochlorite is reported. The phenol formation in a benzene solution containing sodium hypochlorite irradiated wit...
A mechanism for NaCl inhibition of Reactive Blue 19 decolorization and ABTS oxidation by laccase.
Laccases produced by white rot fungi have been extensively evaluated for their potential to decolorize textile wastewaters which contain salts like sodium chloride and sodium sulfate. The effect of so...
